Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13519629 | 0.92 | DAO (0.42) | SIGMAR1HTR7HRH3DAOMAOB | |
| SCHEMBL23384009 | 0.85 | HTR7 (0.49) | SIGMAR1HTR7HRH3DAOPOLB | |
| SCHEMBL13860742 | 0.85 | HTR7 (0.48) | SIGMAR1HTR7HRH3DAOPOLB | |
| SCHEMBL441047 | 0.85 | — | — | |
| SCHEMBL23384522 | 0.83 | HTR7 (0.48) | SIGMAR1HTR7HRH3DAOPOLB | |
| SCHEMBL16750031 | 0.82 | SIGMAR1 (0.44) | SIGMAR1HTR7HRH3DAOPOLB | |
| SCHEMBL21477202 | 0.81 | CHRM5 (0.39) | SIGMAR1HTR7HRH3FPR3FPR2 | |
| SCHEMBL732901 | 0.81 | DAO (0.47) | SIGMAR1HTR7HRH3DAOPOLB | |
| SCHEMBL172560 | 0.80 | CARM1 (0.44) | HRH3 | |
| SCHEMBL12205471 | 0.80 | SIGMAR1 (0.46) | SIGMAR1HTR7HRH3DAOPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | SIGMAR1 4371/4885HTR7 4150/4885HRH3 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.